Jan 26, 2022 / 01:30PM GMT
Operator
Good day, ladies and gentlemen. Thank you for standing by. Welcome to Immunocore's FDA approval of KIMMTRAK webinar. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Brian Di Donato, CFO and Head of Strategy from Immunocore. Please go ahead, sir.
Brian R. Di Donato - Immunocore Holdings plc - CFO & Head of Strategy
Thank you, Kevin. Good morning, and good afternoon, everyone, and thank you for joining us today to discuss the FDA approval of KIMMTRAK.
Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Immunocore's future expectations, clinical development and clinical trials, regulatory approval processes, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated by these forward-looking statements as a result of various
Immunocore Holdings PLC To Discuss FDA Approval Call Transcript
Jan 26, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers